Follow

BioStock Studio: Scandion Oncology and Alligator Bioscience forge preclinical collaboration

24 June 2020 - 09:07

YesterdayNils Brünner, CEO of the Danish Scandion Oncology and Per Norlén, CEO of Swedish Alligator Bioscience came together at the BioStock Studio to discuss their newly forged collaboration. The two companies have recently agreed to explore the anti-tumour effect of Alligator’s mitazalimab in combination with Scandion’s SCO-101 as an addition to chemotherapy in resistant preclinical tumour models. The two CEOs expect that SCO-101 will be able to revert chemotherapy resistance and thereby further strengthen the anti-tumour effects of mitazalimab. 

Watch the video interview with Scandion Oncology's CEO Nils Brünner and Alligator Bioscience's CEO Per Norlén at biostock.se:

https://www.biostock.se/en/biostock-studio-scandion-oncology-and-alligator-bioscience-forge-preclinical-collaboration/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Provided by: Cision
Spotlight (Sweden)
Scandion Oncology A/S
Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date